Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Phase III Clinical Trial to Compare the Efficacy and Safety of UROCOM-R1 Plus UROCOM-R2 Combination Therapy Versus UROCOM-R1 or UROCOM-R2 Monotherapy in Patients With Benign Prostatic Hyperplasia

NCT07870759 is registered in ClinicalTrials.gov with Il-Yang Pharm. Co., Ltd. as lead sponsor.

NCT NCT07870759
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07870759 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Phase III Clinical Trial to Compare the Efficacy and Safety of UROCOM-R1 Plus UROCOM-R2 Combination Therapy Versus UROCOM-R1 or UROCOM-R2 Monotherapy in Patients With Benign Prostatic Hyperplasia
Lead sponsor
Il-Yang Pharm. Co., Ltd.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
November 9, 2026
Completion date
August 31, 2027
Enrollment
660 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

benign prostatic hyperplasia